Chief Executive Officer Eric Adams Said, It’s A Very Devastating Disease And We Found Out In Early Testing That This Set Of Cannabinoids Treat The Major Symptoms Of This Disease Giving Them A Tremendous Amount Of Relief, But It May Also Reverse The Disease, Which Is Something No One Has Really Talked About Before.

Subscribe InMed’s drugs could generate $6 billion a year in revenue, but the company is also attracting attention for its cannabinoid database and biosynthesis manufacturing. (Shutterstock) InMed Pharmaceuticals is a Vancouver-based pre-clinical trial biotech company that has not only developed a proprietary cannabinoid manufacturing system but in the process created a highly sought after database. This database has mapped the different compounds of cannabinoids to the various diseases that it can address. The database was created by InMed to assist them in their research and has now become a core asset as other biotech companies have come knocking on their door willing to pay for this information. Most medical marijuana processors are using THC and CBD because they are easy to extract in a large volume from the plant, but there are over 90 different cannabinoid structures that Marijuana Stocks InMed has plugged into its system. The bioinformatics algorithm has taken those different compounds and screens them against approved drugs, diseases and genetic profiles of diseases. It then selects specific cannabinoids that might help regulate that particular disease. This tool is saving time and money in the drug research process. It has already helped InMed to identify two therapies. One for a rare children’s skin disease called epidermolysis bullosa (EB) that has no approved treatments and the other for glaucoma. Chief Executive Officer Eric Adams said, It’s a very devastating disease and we found out in early testing that this set of cannabinoids treat the major symptoms of this disease giving them a tremendous amount of relief, but it may also reverse the disease, which is something no one has really talked about before. The company is still in its early stages for these drugs with plans to begin clinical trials in 2018 for the EB drug.

To read more visit

Share This Post

Recent Articles

Leave a Reply